TREMFYA (guselkumab) is the First and Only IL-23 Inhibitor to Significantly Reduce Both the Signs and Symptoms and the Progression of Structural Damage in Adults Living With Active Psoriatic Arthritis
April 05, 2025
April 05, 2025
NEW BRUNSWICK, New Jersey, April 5 -- Johnson and Johnson issued the following news release:
* * *
TREMFYA (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
TREMFYA demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Ph . . .
* * *
TREMFYA (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
TREMFYA demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Ph . . .